GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

This is a paid press release. Contact the press release distributor directly with any inquiries.

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

PR Newswire

Mon, February 16, 2026 at 11:00 PM GMT+9 2 min read

In this article:

GRAL.MI

-0.99%

GRAL

+1.68%

MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ – GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on Thursday, Feb. 19, 2026. Following the release, company management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress.

GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

Fourth Quarter and Full Year 2025 Webcast and Conference Call Details

A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL’s website at investors.grail.com.

Please register for the live event at https://grail-q4-financial-results-2025.open-exchange.net/

To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results-302688442.html

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin